• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's After-Market Session

    9/6/22 6:34:19 PM ET
    $APGN
    $AQST
    $ATIP
    $ATXI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $APGN alert in real time by email

    Gainers

    • Metacrine (NASDAQ:MTCR) shares rose 13.8% to $0.54 during Tuesday's after-market session. This security traded at a volume of 3.0 million shares come close, making up 948.6% of its average volume over the last 100 days. The company's market cap stands at $22.7 million.
    • Avenue Therapeutics (NASDAQ:ATXI) stock rose 12.6% to $0.26. Trading volume for this security closed at 64.1K, accounting for 24.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $5.7 million.
    • Aquestive Therapeutics (NASDAQ:AQST) stock increased by 10.39% to $1.38. Trading volume for this security closed at 188.7K, accounting for 20.0% of its average full-day volume over the last 100 days. The company's market cap stands at $73.6 million.
    • Cardiff Oncology (NASDAQ:CRDF) shares increased by 8.62% to $2.77. The company's market cap stands at $120.0 million.
    • Tyme Technologies (NASDAQ:TYME) stock rose 8.22% to $0.27. The company's market cap stands at $46.2 million.
    • Eledon Pharma (NASDAQ:ELDN) shares rose 8.17% to $3.93. The company's market cap stands at $54.0 million.

    Losers

    • Immuneering (NASDAQ:IMRX) stock decreased by 11.6% to $7.31 during Tuesday's after-market session. The company's market cap stands at $192.9 million.
    • Apexigen (NASDAQ:APGN) stock decreased by 8.68% to $6.42. The market value of their outstanding shares is at $137.7 million.
    • First Wave BioPharma (NASDAQ:FWBI) shares declined by 7.11% to $3.92. This security traded at a volume of 2.8 million shares come close, making up 1533.0% of its average volume over the last 100 days. The market value of their outstanding shares is at $5.4 million.
    • ATI Physical Therapy (NYSE:ATIP) stock declined by 6.62% to $0.9. The company's market cap stands at $186.4 million.
    • Rubius Therapeutics (NASDAQ:RUBY) shares fell 6.13% to $0.92. Today's trading volume for this security ended up closing at 6.4 million shares, which is 903.1 percent of its average volume over the last 100 days. The company's market cap stands at $83.1 million.
    • Kazia Therapeutics (NASDAQ:KZIA) shares declined by 5.93% to $1.37. The company's market cap stands at $20.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $APGN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APGN
    $AQST
    $ATIP
    $ATXI

    CompanyDatePrice TargetRatingAnalyst
    Cardiff Oncology Inc.
    $CRDF
    1/5/2026$12.00Outperform
    Noble Capital Markets
    Immuneering Corporation
    $IMRX
    10/31/2025$15.00Outperform
    Leerink Partners
    Cardiff Oncology Inc.
    $CRDF
    7/8/2025$19.00Buy
    Ladenburg Thalmann
    Cardiff Oncology Inc.
    $CRDF
    6/24/2025$3.50Hold
    Jefferies
    Eledon Pharmaceuticals Inc.
    $ELDN
    6/18/2025$9.00Buy
    H.C. Wainwright
    Aquestive Therapeutics Inc.
    $AQST
    6/2/2025$7.00Outperform
    Oppenheimer
    Kazia Therapeutics Limited
    $KZIA
    2/6/2025$3.00Buy
    Maxim Group
    Eledon Pharmaceuticals Inc.
    $ELDN
    1/28/2025$9.00Buy
    Guggenheim
    More analyst ratings

    $APGN
    $AQST
    $ATIP
    $ATXI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Mohindru Mani

    4 - Cardiff Oncology, Inc. (0001213037) (Issuer)

    4/2/26 4:16:32 PM ET
    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Cain David

    3 - KAZIA THERAPEUTICS LTD (0001075880) (Issuer)

    4/1/26 9:20:30 AM ET
    $KZIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Coffey Steven R. S.

    3 - KAZIA THERAPEUTICS LTD (0001075880) (Issuer)

    3/18/26 7:18:21 PM ET
    $KZIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APGN
    $AQST
    $ATIP
    $ATXI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Noble Capital Markets initiated coverage on Cardiff Oncology with a new price target

    Noble Capital Markets initiated coverage of Cardiff Oncology with a rating of Outperform and set a new price target of $12.00

    1/5/26 9:06:54 AM ET
    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Leerink Partners initiated coverage on Immuneering with a new price target

    Leerink Partners initiated coverage of Immuneering with a rating of Outperform and set a new price target of $15.00

    10/31/25 8:20:02 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ladenburg Thalmann initiated coverage on Cardiff Oncology with a new price target

    Ladenburg Thalmann initiated coverage of Cardiff Oncology with a rating of Buy and set a new price target of $19.00

    7/8/25 8:35:06 AM ET
    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APGN
    $AQST
    $ATIP
    $ATXI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Business Officer Brakewood Harold Eugene bought $24,990 worth of shares (5,250 units at $4.76), increasing direct ownership by 91% to 11,050 units (SEC Form 4)

    4 - Immuneering Corp (0001790340) (Issuer)

    1/21/26 9:09:57 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Schall Thomas J. bought $101,041 worth of shares (21,645 units at $4.67), increasing direct ownership by 41% to 74,530 units (SEC Form 4)

    4 - Immuneering Corp (0001790340) (Issuer)

    1/20/26 9:17:29 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF SCIENTIFIC OFFICER Hall Brett Matthew bought $10,502 worth of shares (2,298 units at $4.57), increasing direct ownership by 0.61% to 376,496 units (SEC Form 4)

    4 - Immuneering Corp (0001790340) (Issuer)

    1/16/26 4:07:43 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APGN
    $AQST
    $ATIP
    $ATXI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aquestive Therapeutics Announces Completion of Type A Meeting with FDA for Anaphylm™ (dibutepinephrine) Sublingual Film

    Reaffirms guidance to resubmit the Anaphylm NDA in Q3 2026Received clarifying feedback from the FDA on pharmacokinetic (PK) and human factor (HF) study designsFinal FDA meeting minutes expected by early May 2026 WARREN, N.J., March 30, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the receipt of preliminary comments and successful completion of an in-person Type A meeting with the U.S. Food and Drug Administration (FDA) regarding the resubmission of the Company's New Drug

    3/30/26 7:00:00 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer

    Thomas A. Zalewski, a Partner at Day Pitney LLP, appointed Chief Legal Officer and Chief Compliance Officer effective April 2, 2026Lori J. Braender to remain in a non-executive role as Corporate Secretary after nearly eight years as Chief Legal Officer, Chief Compliance Officer and Corporate Secretary WARREN, N.J., March 20, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer, effective Apr

    3/20/26 7:00:00 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cardiff Oncology to Host Key Opinion Leader Discussion Focusing on First-Line RAS-mutated Metastatic Colorectal Cancer

    SAN DIEGO, March 20, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that the Company will host a key opinion leader (KOL) webinar to discuss the emergent treatment landscape in first-line RAS-mutated metastatic colorectal cancer (mCRC). The webinar will take place on Wednesday, March 25th, 2026, at 4:30 p.m. ET. The webinar will feature KOLs Scott Kopetz, M.D., Ph.D., FACP and Heinz-Josef Lenz, M.D., who will join Mani Mohindru, PhD, interim Chief Executive Officer, to discuss onvansertib's existing clinical data and its potential as a nov

    3/20/26 7:00:00 AM ET
    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APGN
    $AQST
    $ATIP
    $ATXI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for LIBERVANT issued to AQUESTIVE THERAPEUTICS INC

    Submission status for AQUESTIVE THERAPEUTICS INC's drug LIBERVANT (ORIG-1) with active ingredient DIAZEPAM has changed to 'Approval' on 04/26/2024. Application Category: NDA, Application Number: 218623, Application Classification: Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval

    4/29/24 7:48:13 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APGN
    $AQST
    $ATIP
    $ATXI
    SEC Filings

    View All

    Cardiff Oncology Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update

    8-K - Cardiff Oncology, Inc. (0001213037) (Filer)

    4/2/26 4:15:28 PM ET
    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B3 filed by Kazia Therapeutics Limited

    424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)

    3/31/26 7:00:22 PM ET
    $KZIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B3 filed by Kazia Therapeutics Limited

    424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)

    3/31/26 6:59:18 PM ET
    $KZIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APGN
    $AQST
    $ATIP
    $ATXI
    Leadership Updates

    Live Leadership Updates

    View All

    Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer

    Thomas A. Zalewski, a Partner at Day Pitney LLP, appointed Chief Legal Officer and Chief Compliance Officer effective April 2, 2026Lori J. Braender to remain in a non-executive role as Corporate Secretary after nearly eight years as Chief Legal Officer, Chief Compliance Officer and Corporate Secretary WARREN, N.J., March 20, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer, effective Apr

    3/20/26 7:00:00 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aquestive Therapeutics Appoints Internationally Recognized Allergist Dr. Matthew Greenhawt as Chief Medical Officer

    Board-certified allergist and leading food allergy and anaphylaxis researcher joins Aquestive to support Anaphylm™ (dibutepinephrine) sublingual film NDA resubmission and pipeline WARREN, N.J., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the appointment of Matthew Greenhawt, MD, MBA, MSc, as Chief Medical Officer, strengthening its leadership team as the Company prepares to resubmit its Anaphylm™ New Drug Application (NDA) to the United Stated Food and Drug Admi

    2/18/26 7:00:00 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development

    SAN DIEGO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced a leadership transition designed to support the Company's next phase of growth and advancement toward late-stage development and key clinical and corporate milestones. Mani Mohindru, PhD, a member of Cardiff Oncology's Board of Directors since 2021 and a seasoned biotech executive, has been appointed interim Chief Executive Officer, effective immediately. Mark Erlander, PhD, Chief Executive Officer, and James Levine, Chief Financial Officer, have stepped down from their res

    1/27/26 7:00:00 AM ET
    $CRDF
    $CTMX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $APGN
    $AQST
    $ATIP
    $ATXI
    Financials

    Live finance-specific insights

    View All

    Aquestive Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    Reaffirms guidance to resubmit Anaphylm™ (dibutepinephrine) sublingual film NDA in Q3 2026; Type A meeting with FDA expected to occur within 30 daysOn track to submit regulatory applications for Anaphylm in Canada and the EU in 2026Extends revenue sharing agreement with RTW to June 30, 2027Excluding one-time items, meets 2025 guidance for revenue and non-GAAP adjusted EBITDA lossGuides to end FY2026 with cash and cash equivalents of $70 millionCompany to host investment community conference call on March 5, 2026 WARREN, N.J., March 04, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring m

    3/4/26 4:01:00 PM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update

    Reported positive update from Phase 2 CRDF-004 trial in first-line RAS-mutated mCRC, with the 30 mg onvansertib + FOLFIRI/bev arm demonstrating:• Robust ORR of 72.2% (vs 43.2% with combined SoC of FOLFOX/bev and FOLFIRI/bev)• Significant improvement in PFS over combined SoC (HR: 0.37, p<0.05) Data support selection of 30 mg onvansertib dose in combination with FOLFIRI/bev for planned registrational program; detailed data and registrational plans expected in the first half of 2026 SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today an

    2/24/26 4:30:00 PM ET
    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Aquestive Therapeutics to Report Fourth Quarter 2025 Financial Results and Recent Business Highlights on March 4 and Host Conference Call on March 5 at 8:00 a.m. ET

    WARREN, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it will report results for the fourth quarter ended December 31, 2025 and provide an update on recent developments in its business after market close on Wednesday, March 4, 2026. Management will host a conference call for investors at 8:00 a.m. ET on Thursday, March 5, 2026. To participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webc

    2/24/26 7:00:00 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APGN
    $AQST
    $ATIP
    $ATXI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by ATI Physical Therapy Inc.

    SC 13D/A - ATI Physical Therapy, Inc. (0001815849) (Subject)

    12/17/24 5:51:04 PM ET
    $ATIP
    Hospital/Nursing Management
    Health Care

    Amendment: SEC Form SC 13D/A filed by ATI Physical Therapy Inc.

    SC 13D/A - ATI Physical Therapy, Inc. (0001815849) (Subject)

    12/2/24 4:57:34 PM ET
    $ATIP
    Hospital/Nursing Management
    Health Care

    Amendment: SEC Form SC 13D/A filed by ATI Physical Therapy Inc.

    SC 13D/A - ATI Physical Therapy, Inc. (0001815849) (Subject)

    11/25/24 8:12:55 PM ET
    $ATIP
    Hospital/Nursing Management
    Health Care